PERSPECTIVE THERAPEUTICS INC.
NYSE: CATX (Perspective Therapeutics, Inc.)
Last update: yesterday, 11:49PM3.36
-0.02 (-0.59%)
| Previous Close | 3.38 |
| Open | 3.46 |
| Volume | 455,964 |
| Avg. Volume (3M) | 1,139,114 |
| Market Cap | 249,523,680 |
| Price / Book | 1.01 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -6,383.63% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | 5.20% |
| Total Debt/Equity (MRQ) | 1.34% |
| Current Ratio (MRQ) | 17.02 |
| Operating Cash Flow (TTM) | -53.72 M |
| Levered Free Cash Flow (TTM) | -87.14 M |
| Return on Assets (TTM) | -15.56% |
| Return on Equity (TTM) | -32.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Perspective Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -1.50 |
|
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 18.83% |
| % Held by Institutions | 61.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avidity Partners Management Lp | 30 Jun 2025 | 1,858,596 |
| Nicholson Wealth Management Group, Llc | 30 Jun 2025 | 1,614,283 |
| Affinity Asset Advisors, Llc | 30 Jun 2025 | 1,050,000 |
| Ghost Tree Capital, Llc | 30 Sep 2024 | 750,000 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Aug 2025 | Announcement | Perspective Therapeutics to Participate in Upcoming September Conferences |
| 13 Aug 2025 | Announcement | Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results |
| 24 Jul 2025 | Announcement | Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025 |
| 15 Jul 2025 | Announcement | Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results |
| 21 Jun 2025 | Announcement | Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting |
| 21 Jun 2025 | Announcement | Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |